Preferences help
enabled [disable] Abstract
Number of results
2014 | 9 | 6 | 796-801
Article title

Eosinophilia-myalgia syndrome induced by excessive L-tryptophan intake from cashew nuts

Title variants
Languages of publication
Eosinophilia is characterized by more than 0.5 × 109 eosinophils per liter in the full blood count. A wide range of conditions, from asthma to parasitic infections, autoimmune diseases, and certain forms of cancer, have been known to trigger abnormally high amount of eosinophils. It is essential to reach the correct diagnosis and treat the underlying disease aggresively. Definition of the eosinophilia-myalgia syndrome was offered in 1980s by Centers for Disease Control and Prevention for surveillance purposes, and criteria were revised in 2001, with high specificity. We report a case of 59-year old female who started a special weight-reducing diet regimen that included excessive cashew nut ingestion. Several months after she has presented with periferal blood eosinophilia and constitutional symptoms. Detailed work-up has not found elements for haematological, systemic autoimmune, neoplastic or infectious disease. She was diagnosed with eosinophilia-myalgia syndrome due to extreme L-tryptophan intake, a compound found in the cashew nut’s oil. She responded well to cashew nut withdrawal and steroid therapy. In the follow-up period she remained stable with normal eosinophil count and there was not a need for any specific therapy.
Physical description
1 - 12 - 2014
16 - 8 - 2014
  • University Hospital Center Zagreb, 10000, Zagreb, Croatia
  • University Hospital Center Zagreb, 10000, Zagreb, Croatia
  • University Hospital Center Zagreb, 10000, Zagreb, Croatia
  • University Hospital Center Zagreb, 10000, Zagreb, Croatia
  • [1] Holland SM, Gallin JI. Disorders of Granulocytes and Monocytes. In: Fauci AS et al. [ed.] Harrison’s Principles of Internal Medicine, ed. 17. New York, McGraw-Hill Companies, 2008:383
  • [2] Medsger, T.A. Eosinophilia-myalgia syndrome. In Medscape Reference [online]. Available at:
  • [3] Gotlib J. Eosinophilic disorders: Molecular pathogenesis, new classification and mofern therapy. Best practice & Reasearch Clinical Haematology. 2006;19(3):535–569[Crossref]
  • [4] Allen J.A., Paterson A., Sufit R., et al. Postepidemic eosinophilia-myalgia syndrome associated with L-tryptopan. Arthritis & Rheumatism. 2011; 63(11) 3633–3639[Crossref]
  • [5] de Araujo Guerra Grangeia T, Schweller M, Aparecida Paschoal I, et al. Acute respiratory failure as a manifestation of eosinophilia-myalgia syndrome associated with L-tryptophan intake. J Bras Pulmol. 2007;33(6):747–751[Crossref]
  • [6] Noakes R, Spelman L, Williamsom R. Is the L-tryptophan metabolite quinolonic acid responsable for eosinophilic fasciitis? Clin Exp Med. 2006; 6:60–64[Crossref]
  • [7] Hertzman PA, Clauw DJ, Duffy J. Rigorous new approach to constructing a gold standard for validating new diagnostic criteria, as exemplified by eosinohilia-myalgia syndrome. Ann Intern Med. 2001; 161: 2301–2306[Crossref]
  • [8] Dinic-Uzurov V, Lalosevic V, Milosevic I, et al. [Current differential diagnosis of hypereosinophilic syndrome] Med Pregl. 2007:LX(11–12):581–586[Crossref]
  • [9] Petterson R, Germolec D. Toxic Oli Syndrome: Review of immune aspects of the disease. J of Immunotoxicology. 2005;2(1):51–58[Crossref]
  • [10] Liss M. Eosinophilia. In Medscape Reference [online]. Available at:
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.